Fragment-based Drug Discovery: EVOlution™

Fragment-based drug discovery (FBDD) is a new paradigm in drug discovery that utilizes very small molecules - fragments of larger molecules – to generate efficient starting points for drug discovery and thus requires a highly sensitive screening technology.

Evotec’s FBDD platform (EVOlution^TM) integrates orthogonal screening technologies, namely; biochemical, NMR and SPR in order to test fragments in a high throughput, highly sensitive mode. In addition, Evotec offers access to its library of 30,000 high quality fragments designed and selected by medicinal chemists.

The proven benefits of EVOlution^TM are: increased speed, lower attrition and identification of novel chemical IP for “well-screened” and/or challenging targets.

 EVOlution™ is differentiated through:

• Access to a high quality fragment library consisting of 30,000 fragments that provides tractable starting points for subsequent optimization
• A validated set of capabilities integrating high throughput protein production technology, fragment screening, protein crystallography and fragment optimization expertise
• A portfolio of orthogonal screening technologies that combine proprietary FCS+plus screening, NMR screening with a license to Abbott’s SAR-by-NMR™ technology and SPR
• Access to a number of technologies and expertise for the optimization of fragments into lead molecules

For more information, please contact us at info@evotec.com